Citation Information :
Shrikhande BA, Shrikhande LA. Association between Weight Loss in Obese Indian Adolescent Girls with Polycystic Ovarian Syndrome and Decline in Anti-Müllerian Hormone Concentrations. J South Asian Feder Obs Gynae 2019; 11 (2):110-112.
Objective: Several studies have reported anti-Müllerian hormone (AMH) concentrations in girls with polycystic ovarian syndrome (PCOS), but longitudinal studies of changes in AMH concentrations in relation to change in weight status are lacking in Indian adolescent girls with PCOS. Our objective was to study the longitudinal changes in AMH concentrations in obese Indian adolescent girls with PCOS with respect to weight loss.
Materials and methods: This longitudinal study was conducted at the adolescent clinic of Shrikhande Hospital and Research Centre Pvt Limited, Nagpur, India, from January 2017 to December 2017. 120 obese girls aged 13–19 years (50% with PCOS) were included in the study after obtaining informed consent. Girls with and without PCOS were matched to age, BMI, and weight status. Serum AMH, gonadotropins, testosterone, and oestradiol levels were determined. The intervention consisted of promoting physical activity, delivering nutrition education, and behavior therapy. Normal distribution was tested by the Kolmogorov–Smirnov test for all variables. The primary outcome was the change in AMH concentrations over time.
Results: Obese girls with PCOS demonstrated significantly (p < 0.001) higher AMH concentrations (5.7 ± 3.1 ng/mL) as compared to obese girls without PCOS (2.4 ± 1.3 ng/mL). Participants who had experienced weight loss were found to have significantly lower baseline AMH levels (−1.3 ± 1.8 ng/mL, p = 0.04). An association was also found between degree of weight loss and a decline in AMH levels, with subjects experiencing more weight loss demonstrating a higher decline in AMH level (−10.5 ± 1.1 kg vs −4.0 ± 1.0 kg; p = 0.001).
Conclusion: Anti-Müllerian hormone was increased in Indian obese adolescent girls with PCOS and decreased with weight loss.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47. DOI: 10.1093/humrep/deh098.
Legro RS, Arslanian SA, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565–4592. DOI: 10.1210/jc.2013-2350.
Broer SL, Broekman FJ, et al. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update 2014 Sep–Oct;20(5):688–701. DOI: 10.1093/humupd/dmu020.
Pigny P, Merlen E, et al. Elevated serum level of anti-Müllerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957–5962. DOI: 10.1210/jc.2003-030727.
Nybacka A, Carlstrom K, et al. Serum Anti-Müllerian hormone in response to dietary management and/or physical exercise in overweight/obese women with polycystic ovary syndrome: secondary analysis of a randomized controlled trial. Fertil Steril 2013;100:1096–1102. DOI: 10.1016/j.fertnstert.2013.06.030.
Moran LJ, Harrison CL, et al. Exercise decreases anti-Müllerian hormone in anovulatory overweight women with polycystic ovary syndrome: a pilot study. Horm Metab Res 2011;43:977–979. DOI: 10.1055/s-0031-1291208.
Thomson RL, Buckley JD, et al. The effect of weight loss on anti-Müllerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod 2009;24:1976–1981. DOI: 10.1093/humrep/dep101.
Savas-Erdeve S, Keskin M, et al. Do the anti-Müllerian hormone levels of adolescents with polycystic ovary syndrome, those who are at risk for developing polycystic ovary syndrome, and those who exhibit isolated oligomenorrhea differ from those of adolescents with normal menstrual cycles? Horm Res Paediatr 2016;85:406–411. DOI: 10.1159/000446111.
Rosenfield RL, Wroblewski K, et al. Anti-Müllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril 2012;98:242–249. DOI: 10.1016/j.fertnstert.2012.03.059.
Kim JY, Tfayli H, et al. Anti-Müllerian hormone in obese adolescent girls with polycystic ovary syndrome. J Adolesc Health 2016;60:333–339. DOI: 10.1016/j.jadohealth.2016.10.015.
Vosnakis C, Georgopoulos NA, et al. Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol 2013;29:242–245. DOI: 10.3109/09513590.2012.736557.
Gougeon A, Lefevre B. Evolution of the diameters of the largest healthy and atretic follicles during the human menstrual cycle. J Reprod Fertil 1983;69:497–502. DOI: 10.1530/jrf.0.0690497.
Piouka A, Farmakiotis D, et al. Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009;296:E238–E243. DOI: 10.1152/ajpendo.90684.2008.
Panidis D, Katsikis I, et al. Serum anti-Müllerian hormone (AMH) levels are differentially modulated by both serum gonadotropins and not only by serum follicle stimulating hormone (FSH) levels. Med Hypotheses 2011;77:649–653. DOI: 10.1016/j.mehy.2011.07.005.
Pigny P, Jonard S, et al. Serum anti-Müllerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:941–945. DOI: 10.1210/jc.2005-2076.
Gleicher N, Weghofer A, et al. Discordances between follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) in female infertility. Reprod Biol Endocrinol 2010;8:64. DOI: 10.1186/1477-7827-8-64.
Sir-Petermann T, de Ladron GA, et al. Relationship between anti-Müllerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome. Reprod Sci 2012;19:383–390. DOI: 10.1177/1933719111424444.
Olszanecka-Glinianowicz M, Zachurzok A, et al. Circulating anti-Müllerian hormone levels in daughters of women with and without polycystic ovary syndrome. Horm Res Paediatr 2016;85:372–378. DOI: 10.1159/000444637.
Durlinger AL, Gruijters MJ, et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001;142:4891–4899. DOI: 10.1210/endo.142.11.8486.
La Marca A, Orvieto R, et al. Müllerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004;82:970–972. DOI: 10.1016/j.fertnstert.2004.06.001.